Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
4
×
life sciences
national blog main
new york blog main
new york top stories
4
×
boston top stories
cancer
fda
national top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
startups
biogen
boulder/denver blog main
boulder/denver top stories
clinical trials
deals
deerfield management
detroit blog main
detroit top stories
drug discovery
europe blog main
europe top stories
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
novartis
raleigh-durham blog main
raleigh-durham top stories
sanofi
seattle blog main
seattle top stories
takeda pharmaceutical
texas blog main
What
medicines
4
×
ipo
bio
covid
deal
new
roundup
today
acquisitions
activity
aiming
ambys
announced
approvals
big
biogen
biotech
ceo
clamped
collabs
company’s
control
course
daniel
deadly
debuted
delays
developing
development
discover
diseases
economic
experimental
fast
fda
formed
future
gilead
gilead’s
growing
Language
unset
Current search:
medicines
×
ipo
×
" new york top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?